Related Experiment Video
Updated: May 28, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
HIV Genetic Diversity and Drug Resistance
André F Santos1, Marcelo A Soares1,2
1Laboratório de Virologia Humana, Universidade Federal do Rio de Janeiro, CCS, Bloco A, sala A2-120, Cidade Universitária, Ilha do Fundão, 21949-570, Rio de Janeiro, RJ, Brazil.
Abstract:
Most of the current knowledge on antiretroviral (ARV) drug development and resistance is based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV infections. Cumulative evidence has emerged that different HIV types, groups and subtypes harbor distinct biological properties, including the response and susceptibility to ARV. Recent laboratory and clinical data highlighting such disparities are summarized in this review. Variations in drug susceptibility, in the emergence and selection of specific drug resistance mutations, in viral replicative capacity and in the dynamics of resistance acquisition under ARV selective pressure are discussed. Clinical responses to ARV therapy and associated confounding factors are also analyzed in the context of infections by distinct HIV genetic variants.
Related Concept Videos
Viral Mutations
Retrovirus Life Cycles
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetics of Drug Metabolism: Overview

